OncoMatch/Clinical Trials/NCT07425483
CAR-NK Cells (CL-NK-003) in Pancreatic Cancer
Is NCT07425483 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CL-NK-003 for pancreatic cancer.
Treatment: CL-NK-003 — This is a single-center, open-label, first-in-human, fixed-dose study in patients with pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: EGR1 membrane positive tumor cell rate >40% and expression intensity ≥2+ by IHC (membrane positive tumor cell rate >40% and expression intensity ≥2+)
immunohistochemical detection of eGR1 (membrane positive tumor cell rate >40% and expression intensity ≥2+)
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: adoptive cell therapy
Lab requirements
Blood counts
neutrophils ≥ 1.5×10^9/l, lymphocytes ≥ 0.8×10^9/l, hemoglobin ≥ 100 g/l, and platelets ≥ 75 × 10^9/l
Kidney function
creatinine clearance ≥ lln (cockcroft-gault formula)
Liver function
total bilirubin ≤ 2×uln, alanine aminotransferase ≤ 3×uln, aspartate aminotransferase ≤ 3×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07425483 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior adoptive cell therapy disqualifies patients from enrollment.
Does this trial require EGR1?
Yes, EGR1 membrane positive tumor cell rate >40% and expression intensity ≥2+ by IHC is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages